Abstract
The article describes the results of testing in Kyrgyzstan of innovative drugs jardine and dapazine (sodium-glucose cotransporter type 2 inhibitors) on the basis of the Endocrinological Center at the Ministry of Health of the Kyrgyz Republic. The drugs significantly improved the indicators of glycemic control as part of double and triple hypoglycemic therapy, expanded therapeutic possibilities in patients with DM2 with a long course and unsatisfactory control of the disease. These drugs had a positive effect on blood pressure and weight of patients with DM2.